Euroapi S.A. (EAPIF)
| Market Cap | 96.14M -70.9% |
| Revenue (ttm) | 907.80M -10.0% |
| Net Income | -370.39M |
| EPS | -3.92 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 875 |
| Open | 1.170 |
| Previous Close | 1.510 |
| Day's Range | 1.170 - 1.170 |
| 52-Week Range | 1.170 - 3.590 |
| Beta | 0.96 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About Euroapi
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that use solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; and steroids and hormones substances. It also provides API sol... [Read more]
Financial Performance
In 2025, Euroapi's revenue was 852.60 million, a decrease of -7.25% compared to the previous year's 919.20 million. Losses were -211.20 million, 61.7% more than in 2024.
Financial numbers in EUR Financial StatementsNews
Euroapi Earnings Call Transcript: H1 2026
Net sales declined 13.5% year-over-year to EUR 356 million, with a net loss of EUR 141.5 million driven by transformation costs and impairments. The company expects full-year sales to fall around 10% and Core EBITDA margin to be about 6%, with cost discipline and commercial execution as priorities.
Euroapi Earnings release: H1 2026
Euroapi released its H1 2026 earnings on July 30, 2026, summarizing the period's financial results.
Euroapi Slides: H1 2026
Euroapi has posted slides in relation to its H1 2026 quarterly earnings report, which was published on July 30, 2026.
Euroapi Quarterly report: H1 2026
Euroapi has published its H1 2026 quarterly earnings report on July 30, 2026.
Euroapi Transcript: AGM 2026
The meeting reviewed a challenging year marked by declining revenues, increased losses, and major restructuring. Strategic transformation under the FOCUS-27 plan was accelerated, with a renewed executive team and board, while all resolutions—including compensation and governance changes—were approved.
Euroapi Slides: FY 2026
Euroapi has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 27, 2026.
EUROAPI statement regarding the Brindisi site
Press Release Paris – May 13, 2026 – EUROAPI takes note of local media reports regarding its Brindisi site. As previously communicated, the review of strategic options for certain industrial ass...
EUROAPI - Availability of the 2025 Universal Registration Document
Press Release Availability of the 2025 Universal Registration Document, including the Annual Financial Report Paris – March 27, 2026 – EUROAPI announces the publication of its 2025 Universal Reg...
Euroapi Earnings Call Transcript: H2 2025
Net sales declined 7% to EUR 848 million in 2025, with core EBITDA up 31% to EUR 66.2 million and a margin of 7.8%. Portfolio rationalization and cost discipline drove improved profitability, but a 10% sales decrease is expected in 2026 due to continued Sanofi decline and API discontinuations.
Euroapi Earnings release: H2 2025
Euroapi released its H2 2025 earnings on March 4, 2026, summarizing the period's financial results.
Euroapi Slides: H2 2025
Euroapi has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 4, 2026.
Euroapi Annual report: H2 2025
Euroapi has published its H2 2025 annual report on March 4, 2026.
Euroapi Earnings release: Trading Update
Euroapi released its earnings on December 16, 2025, summarizing the period's financial results.
Abolis Biotechnologies and EUROAPI Enter Into Partnership to Accelerate Pharmaceutical Innovation and Restore European Sovereignty
ÉVRY-COURCOURONNES, France--(BUSINESS WIRE)--Abolis Biotechnologies, a company specializing in industrial solutions using microorganisms, today announced that it has entered into a strategic partnersh...
With Med4Cure, EUROAPI accelerates pharmaceutical innovation at the service of health sovereignty
The project launch event, held at the Vertolaye site, brought together State officials, elected representatives, and several project partners to accelerate pharmaceutical innovation in Europe
Science Based Targets initiative (SBTi) validates EUROAPI's near-term climate targets
September 18, 2025 - EUROAPI's near-term science-based emission reduction targets have been approved by the Science Based Targets initiative (SBTi1), confirming the company's alignment with the Paris ...
Euroapi Earnings Call Transcript: H1 2025
Net sales declined 8.2% year-over-year to EUR 412 million, with core EBITDA margin at 9.6% and a net loss of EUR 28.5 million. H2 is expected to strengthen, driven by HP API sales, CMO activity, and vitamin B12 recovery, while cost discipline and strategic investments continue.
Euroapi Quarterly report: H1 2025
Euroapi has published its H1 2025 quarterly earnings report on July 30, 2025.
Euroapi Earnings release: H1 2025
Euroapi released its H1 2025 earnings on July 30, 2025, summarizing the period's financial results.
Euroapi Slides: H1 2025
Euroapi has posted slides in relation to its H1 2025 quarterly earnings report, which was published on July 30, 2025.
EUROAPI sells Haverhill site to Particle Dynamics as part of its FOCUS-27 transformation plan
Paris – June 30, 2025 – EUROAPI today announced the signing of a share purchase agreement (SPA) for the sale of 100% of EUROAPI UK Ltd, the subsidiary operating its Haverhill manufacturing site, with ...
Frédéric Robert appointed EUROAPI's Chief Commercial Officer overseeing API Solutions and CDMO activities
Paris – June 4, 2025 – EUROAPI, a European leader in the production of active pharmaceutical ingredients (API) and contract development and manufacturing organization (CDMO), is pleased to announce th...
Euroapi Transcript: AGM 2025
The AGM reviewed a challenging 2024 with declining revenues and profitability, but highlighted progress on the Focus 27 transformation plan, improved working capital, and strong support from Sanofi. All resolutions were approved, and management reaffirmed its commitment to profitability, ESG, and growth beyond Sanofi.
Euroapi Slides: FY 2025
Euroapi has posted slides in relation to its FY 2025 quarterly earnings report, which was published on May 21, 2025.
Euroapi Earnings Call Transcript: H2 2024
Net sales fell 10% to EUR 911.9 million in 2024, with core EBITDA margin at 5.5% and a net loss of EUR 130.6 million. Focus 27 plan advanced, with 2025 guidance for steady sales and improved 7-9% EBITDA margin, supported by ongoing cost and portfolio optimization.